No phaseRecruiting
Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers (NOVA)
- Sponsor
- Jung-min Ahn (Academic or other)
- Enrolment
- 2,034 planned
- Conditions
- Coronary Artery Disease
- Interventions
- Sirolimus-Ascorbic Acid Eluting Stent; Everolimus-Eluting Stent
- Ages
- adults, older adults
- Registry
- NCT07566091
Full record on ClinicalTrials.gov
From the registry
The objective of this study is to demonstrate the primary hypothesis that, in patients with chronic and acute coronary syndromes requiring percutaneous coronary intervention (PCI), the novel sirolimus-ascorbic acid eluting stent (D+Storm Novonix) is non-inferior to the standard treatment, the everolimus-eluting stent (Synergy XD), with respect to the incidence of target lesion failure (TLF) at 1 year after treatment, where TLF is defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically driven target-lesion revascularization.
Primary outcomes
- The event rate of Target Lesion Failure
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered